A Phase II, Double-blind, Randomized, Parallel Group, Placebo-controlled Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria
Latest Information Update: 10 Oct 2022
At a glance
- Drugs UB 221 (Primary)
- Indications Chronic urticaria
- Focus Pharmacodynamics
- Sponsors United BioPharma
Most Recent Events
- 05 Oct 2022 Status changed from not yet recruiting to recruiting.
- 29 Sep 2022 Planned End Date changed from 1 Mar 2023 to 31 Dec 2023.
- 29 Sep 2022 Planned primary completion date changed from 1 Mar 2023 to 31 Dec 2023.